SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, and Pfizer Inc. (NYSE: PFE) today announced an exclusive worldwide license and collaboration agreement to develop small-molecule inhi...

Company Raises $145 Million in Eighteen Months to Complete Development and Early Commercialization of Breakthrough DNA Sequencing Platform

SAN DIEGO—January 9, 2020 – Omniome, Inc., developer of an innovative DNA sequencing platform capable of delivering unsurpassed sequencing accuracy, today announced it...

• Indigo raises an additional $200M, comprised of $175M in convertible equity and $25M in debt, bringing its total capital raised to approximately $850M. 

• Since its last financing round in September 2018, Indigo has launched and expanded its key business lines–including Indigo Grain Marketplace, In...

• Phase 1/2 trial ongoing with multiple patients dosed in GB1275 monotherapy dose escalation –

• GB1275 granted Orphan Drug Designation for the treatment of pancreatic cancer by the U.S. Food and Drug Administration –

• Preclinical data for GB1275 featured as cover article in July 3rd edition of S...

Program addresses aggressive cancers with RTK (HER2, ERBB3, FGFR1, FGFR2) and KRAS mutations

SAN DIEGO, November 5, 2019 — eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced the dosing of the first subject in the...

EMERYVILLE, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced data on novel shared tumor-specific neoantigens (TSNA) arising from...

Biotechnology Veteran David Hung, M.D. Launches Stealth Start-Up Focusing on the Foremost Unmet Needs in Oncology

Nuvation Bio's Proprietary Portfolio Includes Seven Novel and Mechanistically Distinct Oncology Programs, Each with Multiple Drug Development Candidates

NEW YORK, Oct. 28, 2019 /PRNewswire/ -- N...

Collaboration will combine Lyell’s technologies with GSK’s pipeline of cell therapies and manufacturing capability

Issued: London and San Francisco

GlaxoSmithKline plc today announced a five-year collaboration with Lyell Immunopharma, a San Francisco biotechnology company, to develop new technologies to imp...

SUNNYVALE, Calif.--(BUSINESS WIRE)--EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the WiSE CRT System for the treatment of heart failure.

he...

• Lead gene therapy candidate significantly reduced seizures and reversed early mortality in preclinical model of Dravet Syndrome

• Company aims to maximize the potential of genomics-driven precision medicine by overcoming key limitations of viral gene therapy

• Financing syndicate comprised of pr...